Northwest Therapeutics seeks additional financing
This article was originally published in Scrip
Executive Summary
Northwest Biotherapeutics hopes to secure more funding to see it through the next two months. The US company, listed on London's AIM, says that it is in advanced stages of negotiations and expects to make an announcement shortly. It would not disclose the amount it needed, but said it might not be able to continue operations if it failed to obtain the funding. Northwest, which develops immunologicals to treat cancers more effectively than existing products, revealed in August that it had a severe shortage of cash (Scrip Online, August 21st, 2008).